The more interesting question is obviously, which blockbuster biologic drugs are on their portfolio. Gal, Bernstein analyst quoted in #msg-34973899, said he suspected they were primarily targeting Rituxan and Enbrel.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.